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Background: Thyroid nodule is a common disorder of the thyroid. Despite their benign nature, they can be
associated with multiple pathologic conditions, including thyroid cancer.
Methods: This cross-sectional study determined the concordance of Ultrasound (TIRADS criteria) and Fine Needle
Aspiration Biopsy (FNA-BETHESDA system) in the assessment of the nontoxic thyroid nodule. A total of 180 subjects
18 years old or older underwent the two diagnostic tests and their results were compared using kappa index.
Results: Participants were mostly women, with average age of 57 years. The frequency of BETHESDA II was 65/180
versus 45/180 in TIRADS 2. In contrast, the highest frequency in category 4-IV was 62/180 for TIRADS 4 versus 41/
180 for BETHESDA IV. The highest concordance was found among the category 2-II classification. The observed
agreement was 87.2% with a linear weighted kappa of 0.69 (95% CI: 0.59-0.79). The heterogeneity analysis showed a
trend towards a higher weighted kappa value in nodules ≥4 cm in males and individuals aged ≥50 years, with
accelerated nodular growth, binding to adjacent structures, vocal folds paralysis, urban origin, and a history of head
and neck radiation therapy.
Conclusions: The TIRADS criteria has a good concordance with the Bethesda system. The ultrasound findings of
benign pathology are aligned with the cytology results. The correct interpretation of the two findings helps the
clinician to reduce the risk of unnecessary invasive procedures in patients with a low probability of presenting
thyroid cancer, while facilitating the identification of patients at higher risk of cancer.
Keywords: Thyroid, Nodule, TIRADS, Bethesda, ConcordanceBackground
A steady increase in the incidence rate of thyroid cancer
has been noted in recent decades all over the world, and
the causes of this increase are still controversial. Thyroid
cancer is the most common endocrine malignancy
(1.0–1.5% of all newly diagnosed cancers in the United
States of America every year are originally thyroid). The
increased frequency in thyroid cancer is almost exclusively
due to the rise in the number of papillary cancers, with no
significant changes in other histologic subtypes [1, 2].* Correspondence: hernandovargasuricoechea@gmail.com
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(http://creativecommons.org/publicdomain/zeThe typical presentation is as small tumors, though
there is a growing incidence of large tumors; it has
been hypothesized that the rise in the incidence of
thyroid cancer is mostly due to improved detection
rather than to a real increase in frequency [3]. Thy-
roid nodule can be defined as a discrete lesion within
the thyroid gland that is radiologically distinct from
the surrounding thyroid parenchyma. It may be soli-
tary, multiple, solid, or cystic, and may or not be
functional. Thyroid nodules are frequent among the
general population and thyroid Ultrasound (US) has
considerably increased the number of cases identified.
Thyroid nodules may be palpated in about 4–8% of
the general population (however, neck palpation isle is distributed under the terms of the Creative Commons Attribution 4.0
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morphology). US identifies the presence of nodules in
19-67% of the cases, and is an accurate method for
the detection of thyroid nodules; however, US has a
low accuracy in differentiating between benign from
malignant thyroid nodules [4]. The sonographic char-
acteristics of a thyroid nodule associated with a
higher likelihood of malignancy include hypoecho-
genicity, increased intranodular vascularity, irregular
margins, microcalcifications, absent halo, and a taller-
than-wide shape measured in the transverse dimen-
sion. Thus, several benign and malignant ultrasound
gray scale and Doppler features have emerged over
the last ten years that may be used in different ways
to assign probabilities, together with a method based
on the Breast Imaging Reporting and Data System
(BIRADS). Likewise, several US Thyroid Imaging
Reporting and Data Systems (TIRADS) have been
proposed for risk stratification of thyroid nodules [5].
The nodules are usually divided into different categor-
ies based on TIRADS and are then referred for Fine-
Needle Aspiration (FNA) Biopsy or follow-up, according
to the variable risk of malignancy. The terminology of
TIRADS was first used by Horvath et al. [6]. They de-
scribed 10 US patterns of thyroid nodules and related
the rate of malignancy based on the pattern. The initial
purpose of TIRADS was to improve patient manage-
ment and cost-effectiveness by avoiding unnecessary
FNA Biopsies in patients with thyroid nodules (Table 1),
with a sensitivity, specificity, positive predictive value,
negative predictive value, and accuracy of 88, 49, 49, 88,
and 94%, respectively. However, its clinical use is still
very limited and its practical application in clinical prac-
tice is questioned. Moreover, FNA Biopsy is the most
accurate method for determining malignancy, and is a
fundamental part of current thyroid nodule evaluation.
The Bethesda System for Reporting Thyroid Cytopathol-
ogy is a standardized reporting system for classifying
thyroid FNA Biopsy results that comprises six diagnostic
categories with unique risks of malignancy and recom-
mendations for clinical management. Since its inception,
the Bethesda System has been widely adopted, each cat-
egory conveys a risk of malignancy and recommended
next steps, though it is unclear if each category also pre-
dicts the type and extent of malignancy (Table 1). Never-
theless, the implementation of this reporting system has
shown significant diagnostic variability, both inter and
intra pathologists, particularly when read as “atypical
cells of undetermined significance, follicular lesion of
undetermined significance, or follicular neoplasm” (also
termed as Bethesda Category III, comprising a heteroge-
neous population of low-risk lesions that contain follicu-
lar cells exhibiting either architectural abnormalities or
nuclear atypia that do not fit into other definitivecytological categories). A recent meta-analysis evaluated
the validity of the Bethesda reporting system and found
97% sensitivity, 50.7% specificity and 68.8% diagnostic
accuracy; the negative and positive predictive values
were 96.3 and 55.9%, respectively [7, 8]. Notwithstanding
the fact that both US and FNA biopsy are widely recom-
mended procedures to study patients with thyroid nod-
ules, the value of the existing concordance between the
two methods has not been established. Consequently,
the purpose of this study was to assess the existing con-
cordance between the two diagnostic methods used in
the initial evaluation of individuals with non-toxic
thyroid nodule (TIRADS and Bethesda systems).
Methods
The overall objective of the study was to determine the
level of concordance between the ultrasound criteria
established under TIRADS (The Thyroid Imaging
Reporting and Data System for US of the thyroid); and
the cytology criteria according to The Bethesda System
for Reporting Thyroid Cytopathology [9, 10]. Additionally,
the study population was characterized from the socio-
demographic point of view, the concordance of the classi-
fication systems was estimated, and the heterogeneity of
the factors influencing the consistency of the various
classification systems was analyzed.
Ethics approval and consent to participate
All personal data were confidential and managed ex-
clusively by the principal investigator, according to
the legal standards on the confidentiality of the med-
ical record and adhering to the rules of the Institu-
tional Review Committee of Human Ethics (reference
number: 221–011). Universidad del Valle, Valle del
Cauca-Colombia.
Design of the study
This was a cross-sectional study to evaluate the con-
cordance between two diagnostic systems (TIRADS and
Bethesda), administered simultaneously to the same in-
dividual. The population consisted of consecutive pa-
tients consulting the outpatient endocrinology, internal
medicine, or general surgery departments at a high com-
plexity referral center, with a diagnosis of nodular or
non-nodular “thyroid dysfunction”. The inclusion cri-
teria were as follows: male and females aged 18 years
and older, with a non-toxic thyroid nodule (ranges for
normal thyroid tests were Thyrotrophin (TSH): 0.4 to 4
mIU/L; Free thyroxine: 0.8 to 1.8 ng/dL, according to
the National Academy of Clinical Biochemistry) identi-
fied either clinically or through imaging [11]. The exclu-
sion criteria were: TIRADS 1 and Bethesda I (Table 1);
Graves-Basedow–associated hyperthyroidism, patients with
toxic thyroid nodular disease, chronic hypothyroidism (with
Table 1 Thyroid imaging reporting and data system (TIRADS) and the Bethesda System for Reporting Cytopathology (ref. 6, 8, 9)
TIRADS BETHESDA
Categories Features Diagnostic Categories Risk of malignancy
TIRADS 1 Normal thyroid gland. I. Nondiagnostic or unsatisfactory. -
TIRADS 2 Benign conditions (0% malignancy). Cyst fluid only.
TIRADS 3 Probably benign nodules (5% malignancy). Virtually acellular specimen.
TIRADS 4 Suspicious nodules (5–80% malignancy rate).
A subdivision into 4a (malignancy between 5
and 10%) and 4b (malignancy between 10
and 80%) was optional.
Other (obscuring blood, clotting artifact, etc.).
TIRADS 5 Probably malignant nodules (malignancy >80%). II. Benign. 0-3
TIRADS 6 Category included biopsy proven malignant nodules. Consistent with a benign follicular nodule
(includes adenomatoid nodule, colloid nodule, etc.).
Consistent with lymphocytic (Hashimoto) thyroiditis
in the proper clinical context.
Consistent with granulomatous (subacute) thyroiditis.
III. Atypia of undetermined significance/follicular lesion
of undetermined significance.
5-15
IV. Follicular neoplasm/"suspicious" for follicular neoplasm.
Specify if Hürthle cell type.
15-30
V. Suspicious for malignancy. 60-75
Suspicious for papillary carcinoma.
Suspicious for medullary carcinoma.








Carcinoma with mixed features.
Metastatic.
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sodium), iatrogenic hyperthyroidism resulting from
high-dose sodium levothyroxine therapy regardless of
the indication; a history of surgically resected thyroid
cancer, and patients with a history of partial thyroid-
ectomy (lobectomy) or subtotal/near total thyroidec-
tomy under levothyroxine sodium therapy (the latter
criterion is based on the fact that a constant high
stimulus of thyroid hormones and the concomitant
TSH suppression in patients with endogenous hyper-
thyroidism and levothyroxine management may im-
pact the size of the thyroid nodules) [12, 13].
This study was supported by the Internal Medicine
Department from The Faculty of medicina of the
Universidad del Cauca (Popayán-Colombia), who pro-
vided funding to conduct the analysis and prepare the
manuscript.Sample size estimate and sampling
To estimate the sample size, matched categories in both
reporting systems were considered. Based on the data
from a pilot study with 32 subjects that met the above
selection criteria, and using the formula below, the N




Pe: Expected percentage of random concordance
Ee: Kappa index standard error [14–16].
A consecutive non-probabilistic sampling was used
based on an initial review of 217 medical records; how-
ever the final analysis was limited to 180 patients and 37
patients were excluded due to:
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demographic information in 26 records.
2. The echography was not reported according to TIRADS
criteria in 4 records.
3. The cytology results were not reported according to
the Bethesda criteria in 5 cases.
4. The ultrasound examination had been done at a
different institution or by a different radiologist in 2
cases.
The source of the information in this study is a regis-
try of consecutive data from an outpatient center for
patients with a diagnosis of thyroid dysfunction. A
standard form collected socio-demographic information,
family and personal history of diseases, in addition to
the data available from the medical record. Patients
undergoing thyroid ultrasound imaging and FNA Biopsy
due to non-toxic nodular thyroid disease were analyzed
in accordance with the medical opinion of the institu-
tion’s study group on thyroid disease (endocrinology,
pathology, radiology and surgery). All patients were in-
formed about the procedure and after signing the in-
formed consent, the thyroid ultrasound was performed,
and the node(s) were sampled according to Crockett’s
FNA Biopsy protocol [17].
The same radiologist read all the tests. One out of
every 20 patients was randomly selected to repeat the
ultrasound examination. The principal researcher inter-
preted the results in accordance with the TIRADS cri-
teria and if the second reading was inconsistent with the
first, a second radiologist was asked for an opinion to ar-
rive at a consensus between the two radiologists and es-
tablish a TIRADS-based ultrasonographic diagnosis. 9 of
the 180 participants were randomly selected to assess
the radiologists’ agreement. One of the nine US results
showed disagreement because the first radiologist re-
ported TIRADS 3, while the second one reported TIR-
ADS 2, based on the original classification. Upon further
analysis the conclusion was TIRADS 3. The material ob-
tained via the FNA Biopsy was placed on a glass slide
previously impregnated with 96% alcohol and then a sec-
ond glass slide was placed on top. The smear was again
immersed in 96% alcohol and then stained using the
Papanicolaou technique. To ensure the quality of the
cytology specimens, the same experienced pathologist
read the slides and reported a diagnosis based on the
Bethesda criteria. One out every ten specimens was ran-
domly selected to be analyzed by a second pathologist.
In case of disagreement between the two pathologists, a
pathologist meeting was convened (five pathologist). The
second pathologist disagreed with two of the 18 speci-
mens subject to a second evaluation; in both cases, the
first pathologist classified the cytology specimen as
Bethesda V, while the second pathologist classified thespecimens as Bethesda VI. Both specimens were fur-
ther evaluated at a pathologist meeting, and the final
classification was Bethesda VI. The radiologists and
the pathologists were blinded to the patients’ medical
record data for both the ultrasound examination and
the FNA biopsy.
Statistical analysis
The weighted Kappa statistical method with a 95% confi-
dence interval and the statistical Z-test were used to
estimate the level of concordance between the two sys-
tems. In order to pursue the Kappa analysis, categories 5
and 6 of both the TIRADS and the Bethesda classifica-
tion were combined since the highest risk for malig-
nancy is usually described in these two categories.
Category 1 in both classifications was excluded from the
selection process because a TIRADS 1 ultrasound exam-
ination is considered normal, and Bethesda I is considered
an unsatisfactory specimen. The purpose of excluding cat-
egory 1 was to avoid invalidating further comparisons since
category 1 is inconclusive, particularly Bethesda I. Conse-
quently, the analysis categories are as follows:
 TIRADS 2: “BENIGN”
 TIRADS 3: “PROBABLY BENIGN”
 TIRADS 4: “SUSPICIOUS”
 TIRADS 5: “PROBABLY MALIGNANT”
 Bethesda II: “BENIGN”.
 Bethesda III: “PROBABLY BENIGN”.
 Bethesda IV: “SUSPICIOUS”.
 Bethesda V: “PROBABLY MALIGNANT”
Weighted Kappa statistic with linear weight was used
to estimate the level of agreement between the two sys-
tems; Kappa with quadratic weighting was used for com-
parative purposes. A descriptive analysis was used to
indicate the distribution of the quantitative variables.
Based on that distribution, the average represented the
central trend and the scatter represented the standard
deviation. The qualitative variables were defined in
terms of percentages by category. A stratified analysis
was performed to explore heterogeneity factors, resulting
in a linear weighted Kappa for the following categories:
Gender, age, nodule size, urban/non-urban origin, accel-
erated nodule growth, vocal folds paralysis, hard nodule,
attached to underlying structures, history of head and
neck radiation therapy, and family history of thyroid
cancer. All the analyses used STATA 10.1
Results
The average age was 57 years old. Over 75% of the par-
ticipants were females and 68.9% came from the urban
area; however, there was a remarkable high frequency of
risk factors for thyroid cancer. (Table 2) The frequency
Table 2 Socio-demographic characteristics and risk factors for
thyroid cancer
Characteristic Frequency
Mean age 57 y (SD:±14y)
Sex Fem: 141 (78.3%)
Male: 39 (21.7%)
Origin Urban: 124 (68.9%).
Non-Urban: 56 (31.1%).
Thyroid cancer family backgrounds N (%)
No 119 (66.1%)
Yes 61 (33.9%)






















2 3 4 5
BETHESDA II 42 19 2 2 65
23.33% 10.56% 1.11% 1.11%
III 3 21 14 1 39
1.67% 11.67% 7.78% 0.56%
IV 0 1 33 7 41
0% 0.56% 18.33% 3.89%
V 0 0 13 22 35
0% 0% 7,22% 12,22%
Total 45 41 62 32 180
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ent for categories 2-II and 4-IV. The frequency of cat-
egory II in Bethesda was 65/180 versus 45/180 in
TIRADS 2. In contrast, the highest frequency in category
4-IV was 62/180 for TIRADS 4 versus 41/180 for Be-
thesda IV. (Table 3) The highest concordance was found
for categories TIRADS 2-Bethesda II (23.33%). None of
the patients classified as TIRADS 2 were rated as
Bethesda IV or V. In contrast, 4 subjects classified as
Bethesda II were classified as TIRADS 4 (n = 2) or V
(n = 2). Of the 35 patients classified as Bethesda V
none were classified as TIRADS 2 or 3, but 3 of the
32 subjects with TIRADS 5 were classified as
Bethesda II (n = 2) or III (n = 1). The weighted Kappa
value according to the linear weights was 0.69 (95%
CI: 0.59–0.79). The overall Kappa and the Kappa with
quadratic weighting were also estimated for compara-
tive purposes. (Table 4) The heterogeneity analysis
showed a trend towards a higher weighted kappavalue in nodules ≥4 cm in males and individuals aged
≥50 years, with accelerated nodular growth, binding
to adjacent structures, vocal folds paralysis, urban ori-
gin, and a history of head and neck radiation therapy
(Tables 5 and 6).
Discussion
This study evaluated the concordance between the
TIRADS and the Bethesda reporting systems on the
non-toxic thyroid nodule. The result showed a “good or
substantial” concordance and the most frequent
consistency was found for categories II and IV. The
kappa index measures the level of inter-observer con-
cordance, or as in this particular case, the concordance
between two diagnostic methods rather than the “qual-
ity” of the observation, so it is not possible to establish
the validity of the resulting classifications. This study ad-
dresses the level of discrepancy, the report categories,
and which categories tend to exhibit a higher frequency
of discrepancies between the two methods. When par-
ticular types of disagreements are more frequent, this in-
formation shall be kept in mind when developing the
kappa index [18, 19]. For this reason, the weighted kappa
analysis was used, without neglecting the fact that
although using weights is logical and attractive, it intro-
duces a component of subjectivity since assigning
weights is subjective and may impact the interpretation
of the data when used for a different population –the
weights assigned may vary based on the frequency of the
disease-. This is evidenced through the variation in the
kappa estimates when weighing is used, and depends on
the weighing method used. The weighted kappa estimate
with linear weights assigned to the categories shows a
value of 0.69. The weighted kappa value based on quad-
ratic weights was higher than the overall kappa or the
linear weighted kappa (the quadratic weighted kappa
value was 0.80). The difference is based on the fact that
the linear and quadratic methods are based on the rela-
tive separation among the classification categories but
Table 4 Kappa comparison according to the estimation method
Kappa Observed Agreement Expected agreement Kappa Standard error IC 95% Z Value p
Global 65.56% 25.27% 0.5391 0.0425 0.46–0.62 12.68 <0.001
Weighted (linear weights) 87.22% 58.76% 0.6901 0.0528 0.59–0.79 13.07 <0.001
Estimated (quadratic weights 94.63% 72.86% 0.8021 0.0731 0.66–0.94 10.97 <0.001
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the linear approach uses absolute values [20, 21]. Conse-
quently, quadratic weights tend to assign a higher weight
to disagreements that were relatively few in this study;
when the kappa interpretation is based on quadratic
weights, the level of concordance remains unchanged
versus the interpretation of the linear weighted kappa;
but if analyzed as an absolute value, it is evidently over-
estimated. Since the kappa value is affected by the preva-
lence of the characteristic studied, caution is of the
essence when generalizing the results of inter-observer
comparisons in the presence of varying prevalence. The
prevalence of malignancy based on cytology findings
(Bethesda V in the matched scale) was reported at 19.4%
(35/180); however, using the TIRADS scale (maximum
value of 5 in the matched scale), the prevalence of malig-
nancy was 17% (32/180), showing a non-significant dif-
ference between the two methods. This is extremely
relevant when considering that a prevalence of close to
50% results in a higher kappa value for the same propor-
tion of agreements observed [22, 23]. Thus, the inter-
pretation of the kappa index requires identifying the
value of the marginal frequencies on the table (preva-
lence observed per observer). Since the difference be-
tween the prevalence estimated by both methods is not
significant, the conclusion is than that the prevalence of
the event did not affect the kappa value reported. When
evaluating heterogeneity based on characteristics such as
gender, age, size of the nodule, place of origin, acceler-
ated nodular growth, vocal folds paralysis, hard nodule,
binding to adjacent structures, a history of head andTable 5 Stratification according to nodule size, sex, and age in









<4 cm 85.63% 65.15% 0.5876 0.067 0.46-0.72
≥4 cm 89.67% 66.26% 0.6938 0.083 0.53-0.86
Sex
Men 89.74% 58.32% 0.7539 0.117 0.53-0.98
Women 86.52% 59.30% 0.6689 0.059 0.55-0.78
Age
<50 years old 82.49% 59.91% 0.5632 0.092 0.38-0.74
≥50 years old 89.53% 59.18% 0.7435 0.064 0.62-0.87neck radiation therapy, a family history of thyroid can-
cer, the trend indicates a stronger concordance
(expressed as a weighted kappa value). This is also the
case for variables such as nodule size ≥4 cm, male gen-
der, and age ≥50 years. Despite this trend, the study
failed to show statistically significant differences. The
TIRADS classification attempts to improve the inter-
pretation of the findings of a thyroid nodule by defining
categories that in the end are exclusive, although the
original classification indicates a risk of malignancy be-
tween 5-80% for TIRADS 4, and this fact makes it diffi-
cult to clinically define a follow-up and management
strategy. Notwithstanding this consideration, from the
clinical perspective, in a subject with low probability of
having thyroid cancer (and a TIRADS 2 or 3) the US
negative predictive value will be greatly enhanced. The
best US diagnostic performance is probably with ex-
treme results of the classification (TIRADS 2–3 and
TIRADS 5–6 of the original classification). Depending
on the clinical probability of malignancy, the US findings
may be more or less useful and applicable [24].
Previous studies have evaluated the diagnostic per-
formance of both US and FNA Biopsy in the initial study
of thyroid nodules. A recent study was aimed at devel-
oping a diagnostic algorithm using the data reported in
the US (in accordance with a scoring system evaluating
the risk of malignancy based on several US patterns) and
the results of the FNA Biopsy (according to Bethesda).
This study showed that classifying an individual in ac-
cordance with the presence of different US patterns as
low, intermediate or high risk, together with the results
of the FNA Biopsy, enables optimal clinical decision-
making with regards to treatment strategies [25]. Along
the same lines, other studies classify the risk of malig-
nancy in accordance with the US characteristics and
based on such risk, establish the need to perform a
FNA Biopsy. The higher the risk of malignancy (ac-
cording to the US) the greater the need to do the
FNA Biopsy, and vice-versa –the lower the risk of
malignancy based on the US, the lower the indication
for a FNA Biopsy– [26–28].
Our study showed that the highest concordance was
found among both the lowest risk (TIRADS 2 and Bethesda
II) and the higher risk categories (TIRADS 4 and Bethesda
IV), which is consistent with the previously described trials.
This indicates that the US characteristics suggesting a higher
or lower risk of malignancy, will be associated with higher
Table 6 Heterogeneity assessment by stratifying the variables according to: thyroid cancer family history, accelerated growth of the
nodules, firm nodule, underlying structure, vocal chords paralysis, origins, and history of radiation
Strata Observed Agreement Expected Agreement Kappa Standard Error 95% CI
Thyroid Cancer Family history
Yes 87.98% 60.71% 0.694 0.086 0.53–0.86
No 86.83% 58.81% 0.680 0.066 0.55–0.81
Accelerated Growth of the nodule
Yes 90.40% 60.12% 0.759 0.090 0.58–0.94
No 85.67% 59.89% 0.643 0.065 0.52–0.77
Firm Nodule
Yes 86.82% 58.55% 0.682 0.076 0.53–0.83
No 87.59% 60.10% 0.689 0.073 0.55–0.83
Adjacent Structure Attachment
Yes 94.00% 65.52% 0.826 0.096 0.64–1.01
No 84.62% 59.42% 0.621 0.062 0.50–0.74
Vocal Chords Paralysis
Yes 94.67% 66.11% 0.843 0.096 0.65–1.03
No 84.36% 58.52% 0.623 0.062 0.50–0.74
Origin
Urban (exclusive) 88.70% 58.99% 0.7245 0.065 0.60–0.85
Urban or Rural 84.41% 58.26% 0.6265 0.0881 0.45–0.8
Head and neck radiation therapy
Yes 96.08% 61.48% 0.8982 0.1689 0.57–1.23
No 86.30% 58.55% 0.6695 0.0557 0.56–0.78
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Biopsy report (Bethesda), respectively.
Finally, the interpretation of the results in this study re-
quires acknowledging that over two thirds of the subjects
were women. Probably this trend is due to the fact that
autoimmune thyroid disease is significantly more frequent
in females than in males, so these patients with auto-
immune thyroid disease visit the physician more often in-
creasing the probability of detecting the nodules either
through palpation or ultrasound; clinically this situation
may be defined as a “medical surveillance bias” [29, 30].
The geographical distribution indicates that most of the pa-
tients were from urban areas and those from the rural areas
were mostly from municipalities with accessible specialized
care. The participants in the study had information about
exposure/disease since they had been referred for a study of
the thyroid nodule with a probable diagnosis of malignancy.
In cross-section studies the participants may be more prone
to participate based on their knowledge about exposure
and disease and the convenience of their geographical loca-
tion leading to a higher “selection bias” that in turn could
overestimate the frequency of malignancies [31, 32]. This
study highlights the high frequency of factors that have
been historically associated with thyroid cancer. Those fac-
tors were evaluated with the survey administered to thestudy subjects that had been previously referred for tests to
rule out malignancies, so these participants were more
likely to recall past exposures (accurate or vague) poten-
tially leading to a “recall bias” [30, 33]. Furthermore, since
the data collection from the participants was not masked
(they had been previously identified as nodular thyroid dis-
ease patients screened for malignancies), the interviewer’s
interest in evaluating the exposure factors could have re-
sulted in an “interviewer bias” [34, 35].
Conclusions
The thyroid ultrasound report using the TIRADS criteria
has a good concordance with the Bethesda cytology find-
ings using FNA Biopsy. The ultrasound findings of benign
pathology are aligned with the cytology results and vice-
versa; ultrasound findings of malignancy shall be consistent
with cytology-identified malignant disease. The correct in-
terpretation of the two findings helps the clinician to re-
duce the risk of unnecessary invasive procedures in patients
with a low probability of presenting thyroid cancer, while
facilitating the identification of patients at higher risk of
cancer. There is a need to develop study and monitoring
protocols for cases classified as “discordant”, particularly
when extreme categories are identified (TIRADS 5-
Bethesda II, TIRADS 2-BethesdaV).
Vargas-Uricoechea et al. Thyroid Research  (2017) 10:1 Page 8 of 9Abbreviations
BIRADS: Breast Imaging Reporting and Data System; FNA: Fine-Needle
Aspiration; TIRADS: The Thyroid Imaging Reporting and Data System for US




This study was supported by the Internal Medicine Department from The
Faculty of medicina of the Universidad del Cauca (Popayán-Colombia), who
provided funding to conduct the analysis and prepare the manuscript.
Availability of data and materials
We are reluctant to share this data in a publicly accessible repository as this
would breech patient confidentiality according to the terms of governance
approval for the study: Rules of the Institutional Review Committee of
Human Ethics (reference number: 221–011). Universidad del Valle, Valle del
Cauca-Colombia.
Authors’ contributions
H V-U, I M-C and J H-Ch were involved in study design, acquisition of data,
analysis and interpretation of data and drafting and revising the manuscript.
H V-U, and I M-C were involved in data collection and analysis and manuscript
drafting. All authors read and approved the final manuscript.
Competing interests
All authors declare no financial competing interests, nor any other type of
conflicts of interest.
Consent for publication
All authors gave their approval for the final version to be published and
agree to be accountable for this work.
Ethics approval and consent to participate
All personal data were confidential and managed exclusively by the principal
investigator, according to the legal standards on the confidentiality of the
medical record and adhering to the rules of the Institutional Review Committee
of Human Ethics (reference number: 221–011). Universidad del Valle, Valle del
Cauca-Colombia.
Author details
1Department of Internal Medicine, Division of Endocrinology and
Metabolism, Universidad del Cauca, Popayán, Colombia. 2Laboratory of
Pathology, Hospital Universitario San José, Popayán, Cauca, Colombia.
3Department of surgery, Universidad del Cauca, Carrera 6 No 41 N-135 apto
202B terrazas del campestre, Popayán, Cauca, Colombia.
Received: 24 October 2016 Accepted: 24 January 2017
References
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM,
Forman D, Bray F. Cancer incidence and mortality worldwide: sources,
methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):
359–86.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer
statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.
3. Wiltshire JJ, Drake TM, Uttley L, Balasubramanian SP. Systematic review of
trends in the incidence rates of thyroid cancer. Thyroid. 2016;26(11):1541–52.
4. Gharib H, Papini E, Garber JR, Duick DS, Harrell RM, Hegedüs L, Paschke R,
Valcavi R, Vitti P, AACE/ACE/AME Task Force on Thyroid Nodules. American
Association Of Clinical Endocrinologists, American College Of
Endocrinology, And Associazione Medici Endocrinologi Medical Guidelines
For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules–
2016 Update. Endocr Pract. 2016;22(5):622–39.
5. Yoon JH, Lee HS, Kim EK, Moon HJ, Kwak JY. Malignancy risk stratification of
thyroid nodules: comparison between the thyroid imaging reporting and
data system and the 2014 American thyroid association management
guidelines. Radiology. 2016;278(3):917–24.6. Horvath E, Majlis S, Rossi R, Franco C, Niedmann JP, Castro A, Dominguez M.
An ultrasonogram reporting system for thyroid nodules stratifying cancer
risk for clinical management. J Clin Endocrinol Metab. 2009;94(5):1748–51.
7. Pusztaszeri M, Rossi ED, Auger M, Baloch Z, Bishop J, Bongiovanni M,
Chandra A, Cochand-Priollet B, Fadda G, Hirokawa M, Hong S, Kakudo K,
Krane JF, Nayar R, Parangi S, Schmitt F, Faquin WC. The Bethesda system for
reporting thyroid cytopathology: proposed modifications and updates for
the second edition from an international panel. Acta Cytol. 2016;60(5):399–405.
8. Garg S, Desai NJ, Mehta D, Vaishnav M. To establish bethesda system for
diagnosis of thyroid nodules on the basis of fnac with histopathological
correlation. J Clin Diagn Res. 2015;9(12):EC17–21.
9. Russ G, Bigorgne C, Royer B, Rouxel A, Bienvenu-Perrard M. The Thyroid
Imaging Reporting and Data System (TIRADS) for ultrasound of the thyroid.
J Radiol. 2011;92(7–8):701–13.
10. Cibas ES, Ali SZ. NCI Thyroid FNA State of the Science Conference. The
Bethesda System for reporting thyroid cytopathology. Am J Clin Pathol.
2009;132:658–65.
11. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry
JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt
JR, Guidelines Committee, National Academy of Clinical Biochemistry.
Laboratory medicine practice guidelines. Laboratory support for the
diagnosis and monitoring of thyroid disease. Thyroid. 2003;13(1):3–126.
12. Zelmanovitz F, Genro S, Gross JL. Suppressive therapy with levothyroxine for
solitary thyroid nodules: a double-blind controlled clinical study and
cumulative meta-analyses. J Clin Endocrinol Metab. 1998;83:3881–5.
13. Grussendorf M, Reiners C, Paschke R, Wegscheider K. Reduction of thyroid
nodule volume by levothyroxine and iodine alone and in combination: a
randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2012;96:2786–95.
14. Kramer M, Feinstein AR. Clinical Biostatistics. The biostatistics of concordance.
Clin Pharmacol Ther. 1981;29:111–23.
15. Cantor AB. Sample-size calculation for Cohen’s kappa. Psychol Methods.
1996;1:150–3.
16. Sim J, Wrigth CC. The Kappa statistic in reliability studies: Use, interpretation,
and sample size requirements. Phys Ther. 2005;85:257–68.
17. Crockett JC. The thyroid nodule fine-needle aspiration biopsy technique.
J Ultrasound Med. 2011;30:685–94.
18. Landis JR, Koch GG. The measurement of observer agreement for categorical
data. Biometrics. 1977;33:159–74.
19. Barnhart HX, Williamson JM. Weighted least-squares approach for comparing
correlated kappa. Biometrics. 2002;58(4):1012–109.
20. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb).
2012;22(3):276–82.
21. Cyr L, Francis K. Measures of clinical agreement for nominal and categorical
data: the kappa coefficient. Comput Biol Med. 1992;22(4):239–46.
22. Brenner H, Kliebsch U. Dependence of weighted kappa coefficients on the
number of categories. Epidemiology. 1996;7(2):199–202.
23. Guggenmoos-Holzmann I, Vonk R. Kappa-like indices of observer agreement
viewed from a latent class perspective. Stat Med. 1998;17(8):797–812.
24. Rosario PW. Thyroid Nodules with Atypia or Follicular Lesions of Undetermined
Significance (Bethesda Category III): Importance of Ultrasonography and
Cytological Subcategory. Thyroid. 2014;24:1115–20.
25. Adamczewski Z, Lewiński A. Proposed algorithm for management of patients
with thyroid nodules/focal lesions, based on ultrasound (US) and fine-needle
aspiration biopsy (FNAB); our own experience. Thyroid Res. 2013;6:6.
doi:10.1186/1756-6614-6-6.
26. Cavaliere A, Colella R, Puxeddu E, Gambelunghe G, Falorni A, Stracci F,
d’Ajello M, Avenia N, De Feo P. A useful ultrasound score to select thyroid
nodules requiring fine needle aspiration in an iodine-deficient area. J Endocrinol
Invest. 2009;32(5):440–4.
27. Petrone L, Mannucci E, De Feo ML, Parenti G, Biagini C, Panconesi R, Vezzosi
V, Bianchi S, Boddi V, Di Medio L, Pupilli C, Forti G. A simple ultrasound
score for the identification of candidates for fine needle aspiration of thyroid
nodules. J Endocrinol Invest. 2012;35(8):720–4.
28. Remonti LR, Kramer CK, Leitão CB, Pinto LC, Gross JL. Thyroid ultrasound
features and risk of carcinoma: a systematic review and meta-analysis of
observational studies. Thyroid. 2015;25(5):538–50.
29. Haut ER, Pronovost PJ. Surveillance bias in outcomes reporting. JAMA.
2011;305(23):2462–3.
30. Hoppin JA, Tolbert PE, Taylor JA, Schroeder JC, Holly EA. Potential for selection
bias with tumor tissue retrieval in molecular epidemiology studies. Ann
Epidemiol. 2002;12(1):1–6.
Vargas-Uricoechea et al. Thyroid Research  (2017) 10:1 Page 9 of 931. Holford TR, Stack C. (1995) Study design for epidemiologic studies with
measurement error. Stat Methods in Med Res. 1995;4(4):339–58.
32. Flanders WD, Eldridge RC. Summary of relationships between
exchangeability, biasing paths and bias. Eur J Epidemiol.
2015;30(10):1089–99.
33. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to
bias in observational studies in epidemiology: a systematic review and annotated
bibliography. Int J Epidemiol. 2007;36(3):666–76.
34. Wynder EL. Investigator bias and interviewer bias: the problem of reporting
systematic error in epidemiology. J Clin Epidemiol. 1994;47(8):825–7.
35. Davis RE, Couper MP, Janz NK, Caldwell CH, Resnicow K. Interviewer effects
in public health surveys. Health Educ Res. 2010;25(1):14–26.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
